Clinical characteristics of the cohort of patients with systemic sclerosis and positive anti-RNA polymerase III antibodies from the José de San Martín Hospital de Clínicas
Abstract
Introduction: in systemic sclerosis (SS), autoantibody positivity is useful for diagnosis and classification, being mutually self-exclusive. Objectives: estimate the prevalence of positive anti-RNA polymerase III (anti-RNAP III) antibodies in patients with negative anti-topoisomerase I (ATA) and anti-centromere (ACA) and describe the clinical characteristics. Materials and methods: bidirectional, descriptive, single-center study. We included patients over 18 years of age who met the American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) 2013 classification criteria with ATA and ACA negative. anti-RNAP III was determined by ELISA, QUANTA lite RNA POL III Inova Diagnostics®. Anti-RNAP III positive patients were compared with anti-RNAP III negative patients. Results: 31 patients were included. 48.4% (15/31) anti-RNAP III positive and 51.6% (16/31) negative. The prevalence of positive anti RNAP-III was 5.06%. A higher proportion of digital ulcers (40% vs 25%), amputations (13.3% vs 6.3%), arthritis (33% vs 18.8%), tendon rub (20% vs 7.1%) and gastric antral vascular ectasia (GAVE) were observed. (16.7% vs 0%) in the anti-RNAP III positive group. Conclusions: due to its possible role as a prognostic marker, it seems essential to know the characteristics of our population and especially of our hospital.References
I. Yayla ME, İlgen U, Düzgün N. An analysis of the relationship between autoantibodies and clinical findings in patients with systemic sclerosis. Turk J Med Sci 2018;48(1):10-15.
II. Żebryk P, Przymuszała P, Nowak JK, et al. Autoantibodies and clinical correlations in polish systemic sclerosis patients: a cross-sectional study. J Clin Med 2023;12(2):657.
III. Sobanski V, Dauchet L, Lefèvre G, et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: New data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol 2014;66(2):407-417.
IV. Meyer O, De Chaisemartin L, Nicaise-Roland P, et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010;37(1):125-130.
V. Cavazzana I, Ceribelli A, Airo' P, Zingarelli S, et al. Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression. Autoimmun Rev 2009;8(7):580-584.
VI. Bhavsar SV, Carmona R. Anti-RNA polymerase III antibodies in the diagnosis of scleroderma renal crisis in the absence of skin disease. J Clin Rheumatol 2014;20(7):379-382.
VII. Stern EP, Guerra SG, Chinque H, et al. Analysis of anti-RNA polymerase III antibody-positive systemic sclerosis and altered GPATCH2L and CTNND2 expression in scleroderma renal crisis. J Rheumatol 2020;47(11):1668-1677.
VIII. Parker JC, Burlingame RW, Webb TT, Bunn CC. Anti-RNA polymerase III antibodies in patients with systemic sclerosis detected by indirect immunofluorescence and ELISA. Rheumatology (Oxford) 2008;47(7):976-979.
IX. Liu C, Hou Y, Xu D, et al. Analysis of anti-RNA polymerase III antibodies in Chinese Han systemic sclerosis patients. Clin Rheumatol 2020;39(4):1191-1197.
X. Nandiwada SL, Peterson LK, Mayes MD, et al. Ethnic differences in autoantibody diversity and hierarchy: more clues from a US cohort of patients with systemic sclerosis. J Rheumatol 2016;43(10):1816-1824.
XI. Horimoto AMC, Matos ENN, Costa MRD, et al. Incidence and prevalence of systemic sclerosis in Campo Grande, State of Mato Grosso do Sul, Brazil. Rev Bras Reumatol Engl Ed. 2017;57(2):107-114.
XII. Gargiulo MA, Pérez N, Khoury Marina, Buhl M, et al. Anticuerpos anti-RNA polimerasa III en esclerosis sistémica: estudio multicéntrico de Argentina. Reumatol Clin (Barc) 2022;18(6): 368-373.
XIII. Van den Hoogen F, Khanna D, Fransen J, et al. 2013 Classification criteria for systemic sclerosis: an American College of Rheumatology/European League Against Rheumatism Collaborative Initiative. Ann Rheum Dis 2013;72(11):1747-1755.
XIV. LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28(7):1573-1576. PMID: 11469464.
XV. Khanna D, Furst DE, Clements PJ, et al. Standardization of the modified Rodnan skin score for use in clinical trials of systemic sclerosis. J Scleroderma Relat Disord 2017;2(1):11-18.
XVI. Moinzadeh P, Fonseca C, Hellmich M, et al. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014;16(1):R53.
XVII. Ghrénassia E, Avouac J, Khanna D, et al. Prevalence, correlates and outcomes of gastric antral vascular ectasia in systemic sclerosis: a EUSTAR case-control study. J Rheumatol 2014;41(1):99-105.
Copyright (c) 2024 on behalf of the authors. Reproduction rights: Argentine Society of Rheumatology
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
